Search results for " Hepatitis C."

showing 10 items of 174 documents

Long-term follow-up of hepatitis C virus-positive patients with persistently normal serum transaminases

2013

Material and methods. This study prospectively evaluated the progression of liver disease in a group of anti-HCV-positive patients with persistently normal ALT levels (PNALT) who were HCV-RNA positive. Patients selected for this study were those who presented with PNALT according to the Italian Association for the Study of the Liver (AISF) criteria in the year 1995/96 and underwent liver biopsy. They were divided into two groups according to their ALT evolution. Forty-five patients were included in this study. Results. After a median follow-up time of 180 months twenty-five of them maintained PNALT, but two of these developed liver cirrhosis (LC) in a mean time of 174 and 202 months, respec…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisLong term follow upSpecialties of internal medicineNormal serumChronic hepatitis CGastroenterologyAntiviral AgentsBody Mass IndexLiver diseaseInterferon treatmentInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesUltrasonography Doppler ColorChronic hepatitis C. Persistently normal transaminases. Liver histology. Progression of disease. Interferon treatment.Proportional Hazards ModelsHepatologymedicine.diagnostic_testbusiness.industrySignificant differenceHistologyAlanine TransaminaseGeneral MedicineHepatitis C AntibodiesHepatitis C ChronicMiddle Agedmedicine.diseaseSurgeryHepatitis C Virus PositiveLiverRC581-951Liver biopsyDisease ProgressionElasticity Imaging TechniquesRNA ViralFemaleBiopsy Large-Core NeedlePersistently normal transaminasesbusinessLiver histologyProgression of disease
researchProduct

Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient.

2009

Histopathological scoring of disease stage uses descriptive categories without measuring the amount of fibrosis. Collagen, the major component of fibrous tissue, can be quantified by computer-assisted digital image analysis (DIA) using histological sections. We determined relationships between DIA, Ishak stage, and hepatic venous pressure gradient (HVPG) reflecting severity of fibrosis. One hundred fifteen patients with hepatitis C virus (HCV) who had undergone transplantation had 250 consecutive transjugular liver biopsies combined with HVPG (median length, 22 mm; median total portal tracts, 12), evaluated using the Ishak system and stained with Sirus red for DIA. Liver collagen was expres…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentPortal venous pressureImage ProcessingBiopsyLiver transplantationHepatic VeinsGastroenterologyComputer-AssistedInternal medicineBiopsymedicineImage Processing Computer-AssistedHumansProspective StudiesAgedHepatologymedicine.diagnostic_testbusiness.industryHepatologyMiddle Agedmedicine.diseaseHepatitis CConfidence intervalSurgeryLiver TransplantationTransplantationLogistic ModelsLiverAdult; Aged; Biopsy; Collagen; Female; Hepatic Veins; Hepatitis C; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Prospective Studies; Venous Pressure; Image Processing Computer-AssistedFemaleCollagenTransient elastographybusinessVenous Pressurecollagen proportionate area HVPG liver fibrosisHepatology (Baltimore, Md.)
researchProduct

Fibrosis staging in chronic hepatitis C: Analysis of discordance between transient elastography and liver biopsy

2009

Summary.  In chronic hepatitis C, transient elastography (TE) accurately identifies cirrhosis, but its ability to assess significant fibrosis (Metavir ≥ F2) is variable. Constitutional and liver disease-related factors may influence TE and here we examined the variables associated with differences. Three hundred consecutive hepatitis C virus (HCV)-RNA positive patients had biochemical tests, TE and a biopsy performed on the same day. The Dale model was used to identify the variables associated with discordance between biopsy and elastography results. In 97 patients (34.2%), TE and histological assessment were discordant. Seventy-six of 286 (26.6%) had stage ≥F2 and TE < 7.1 kPa (false negat…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisTransient elastographyHepatitis C virusBiopsyLiver fibrosismedicine.disease_causeGastroenterologySeverity of Illness IndexAminotranferases; Liver fibrosis; Transient elastography; Adult; Diagnostic Errors; Female; Hepatitis C Chronic; Histocytochemistry; Humans; Liver Cirrhosis; Male; Middle Aged; ROC Curve; Transaminases; Biopsy; Elasticity Imaging Techniques; Severity of Illness Index; Hepatology; Infectious Diseases; Virology; Medicine (all)Liver diseaseInternal medicineVirologyBiopsymedicineHumansDiagnostic ErrorsChronicAminotranferases liver fibrosis transient elastographyTransaminasesmedicine.diagnostic_testReceiver operating characteristicHepatologybusiness.industryHistocytochemistryMedicine (all)Hepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CInfectious DiseasesROC CurveLiver biopsyAminotranferasesElasticity Imaging TechniquesFemaleTransient elastographybusiness
researchProduct

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus …

2012

Background. Polymorphisms in the interleukin-28B are important determinants in the spontaneous and drug-induced control of hepatitis C virus infection. Design and Methods. We assessed the association of rs8099917 and rs12979860 polymorphisms with spontaneous viral clearance, severity of liver fibrosis, and response to interferon-monotherapy in 245 Thalassemia Major patients with Hepatitis C Virus infection. Results. Ninety-eight patients (40%) had a spontaneous viral clearance, while 147 patients (60%) developed a chronic infection. Spontaneous viral clearance was more frequent among patients with the T/T genotype of rs8099917 polymorphism (OR 2.130; p=0.008) or C/C genotype of rs12979860 p…

AdultLiver CirrhosisMalethlassemia hepatitis CInterferon InducersAdolescentHepacivirusHepatitis C virusAlpha interferonHepacivirusAdolescent; Adult; Antibodies Viral; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Chronic; Humans; Interferon Inducers; Interferon-alpha; Interleukins; Liver Cirrhosis; Male; Polymorphism Single Nucleotide; Prognosis; Viral Load; Young Adult; beta-Thalassemiamedicine.disease_causeAntibodies ViralAntiviral AgentsPolymorphism Single NucleotideCohort StudiesYoung AdultGenotypemedicineHumansInterferon inducerbiologymedicine.diagnostic_testInterleukinsbeta-ThalassemiaInterferon-alphaHematologyHepatitis CHepatitis C ChronicViral Loadbiology.organism_classificationmedicine.diseasePrognosisLiver biopsyImmunologyFemaleInterferonsOriginal Articles and Brief ReportsViral loadFollow-Up Studies
researchProduct

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

2012

Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b, with ∼200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized 3:4:4:4 to one of four open-label treatment groups: pegylated IFN (Peg-IFN)-α-2a 180 μg qwk or albIFN 900, 1200 or 1500 μg q4wk, plus oral ribavirin 800 mg/day, for 24 weeks. Primary efficacy endpoint was sustained virologic response (SVR; HCV RNA <20 IU/mL 24 weeks post-treatment). SVR rates were as follows: 85%, 76%, 76% and 78% with Peg-IFNα-2a and albIFN 900, 1200 and 1500 μg, respectively (P = NS); c…

AdultMaleANTIVIRAL TREATMENTGenotypeInterleukinsInterferon-alphaHepacivirusHepatitis C ChronicMiddle AgedViral LoadAntiviral AgentsAlbinterferon alfa-2bTreatment OutcomeAlbuminsHumansRNA ViralFemaleInterferonshepatitis CAlbinterferon alfa-2b; hepatitis c; ANTIVIRAL TREATMENT
researchProduct

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey

2018

BACKGROUND: In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and therapeutic data from patients affected by haemophilia A (HA), haemophilia B (HB), von Willebrand’s disease (vWD) and other rare coagulation disorders. Here we present data from the 2016 annual survey. MATERIALS AND METHODS: Data are provided by the Italian Haemophilia Centres, on a voluntary basis. Information flows from every Centre to a web-based platform of the Italian Association of Haemophilia Centres, shared with the Italian National Institute of Health, in accordance with current privacy laws. Patients are classified by diagnosis, disease severity, age, gender and treatment-r…

AdultMaleCanadaAdolescentAdolescent Adult Aged Blood Coagulation Factors Canada Child Coagulation Protein Disorders Factor IX Factor VIII Female France HIV Infections Hemophilia A Hemophilia B Hepatitis CHumans Infant Infant Newborn Italy Male Middle Aged Prevalence Registries Surveys and Questionnaires United Kingdom von Willebrand DiseasesHIV InfectionsCoagulation Protein DisordersHemophilia AHemophilia BFactor IXhemic and lymphatic diseasesSurveys and QuestionnairesPrevalenceHumansRegistriesChildAgedFactor VIIIInfant NewbornInfantMiddle AgedHepatitis CBlood Coagulation FactorsUnited Kingdomvon Willebrand DiseasesItalyChild PreschoolFemaleOriginal ArticleFrance
researchProduct

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C

2003

Occult HBV infection in subjects with chronic hepatitis C is related to more severe disease outcome. It has been suggested that it might reduce sensitivity to antiviral treatment.To assess in HBsAg negative subjects with chronic hepatitis C any effect of the presence of HBV genomes in the liver on the early kinetics of HCV-RNA under PEG-IFN plus ribavirin.Twenty-two anti-HCV and HCV-RNA positive subjects, with biopsy-proven chronic hepatitis C (M/F 15/7; 50 +/- 8.6 years, 16 genotype 1b) were given PEG-IFN alpha 2b 1.0 microg qw plus ribavirin (800 to 1,200 mg daily according to body weight) for an intended 52 week period. Early virological response was assessed over the first 4 weeks of th…

AdultMaleHepatitis B viruspegylated interferon-alphaGenotypeBiopsyHepacivirusInterferon alpha-2Virus ReplicationAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodieRibavirinchronic hepatitis CHumansHepatitis B AntibodiesAntiviral AgentHepaciviruoccult HBV infection; chronic hepatitis C; pegylated interferon-alpha; viral dynamics; treatment responseoccult HBV infectiontreatment responseInterferon-alphaAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesHepatitis C ChronicMiddle AgedRecombinant ProteinViral LoadHepatitis Bviral dynamicsRecombinant ProteinsTreatment OutcomeLiverDNA ViralRNA ViralDrug Therapy CombinationFemaleHepatitis C AntibodieHuman
researchProduct

Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interfe…

2001

&lt;i&gt;Objectives:&lt;/i&gt; Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization…

AdultMaleIntercellular Adhesion Molecule-1Alpha interferonInflammationInterferon alpha-2BiologyChronic hepatitis CAntiviral Agentsα-InterferonLiver diseaseChronic hepatitisVirologymedicineHumansAspartate Aminotransferasesα interferonInterferon-alphaAlanine TransaminaseAdhesionIntercellular adhesion molecule-1Hepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsInfectious DiseasesImmunologyCancer researchFemalemedicine.symptomLiver diseaseIntracellular
researchProduct

Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection.

2009

Summary.  B-lymphocyte stimulator/B activating factor (BLyS/BAFF) is a tumour necrosis factor-family cytokine that plays a key role in generating and maintaining the mature B-cell pool. BLyS/BAFF expression by macrophages is stimulated by interferon-γ and interleukin-10, and its serum levels are increased in chronic hepatitis C (CHC). The aim of this study was to assess serum levels of BLyS/BAFF in patients with acute hepatitis C (AHC) and correlate them with disease outcome. We studied 28 patients with AHC (14 males, mean age 59.3 ± 15 years), followed for at least 7 months since onset, comparing them with 86 CHC patients and 25 healthy blood donors (HBD). BLyS/BAFF levels were assessed at…

AdultMaleNecrosismedicine.medical_treatmentAcute hepatitis CVirusYoung AdultVirologyB-Cell Activating FactorMedicineHumansIn patientB-cell activating factorAgedAged 80 and overHepatologybusiness.industryHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CChronic infectionInfectious DiseasesCytokineImmunologyFemaleAcute hepatitis Cmedicine.symptombusinessBiomarkersJournal of viral hepatitis
researchProduct

Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience

2010

AdultMalePediatricsmedicine.medical_specialtyCarcinoma HepatocellularIron OverloadCirrhosisThalassemiaCarcinomaHumansMedicineAgedbusiness.industryLiver NeoplasmsTransfusion ReactionCancerHematologyHepatitis CHepatitis C ChronicMiddle AgedPrognosismedicine.diseaseSurgeryHemoglobinopathyHepatocellular carcinomaThalassemiaThalassaemia hepatocellular carcinoma iron overload cirrhosis hepatitis CFemalebusinessLiver cancer
researchProduct